Cargando…

Inhibition of the hedgehog pathway for the treatment of cancer using Itraconazole

Itraconazole (ITZ) is an anti-fungal drug that has been used in clinical practice for nearly 35 years. Recently, numerous experiments have shown that ITZ possesses anti-cancer properties. The Hedgehog (Hh) pathway plays a pivotal role in fundamental processes, including embryogenesis, structure, mor...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Ke, Fang, Dengyang, Xiong, Zuming, Luo, Runlan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6711563/
https://www.ncbi.nlm.nih.gov/pubmed/31692536
http://dx.doi.org/10.2147/OTT.S223119
_version_ 1783446539783372800
author Li, Ke
Fang, Dengyang
Xiong, Zuming
Luo, Runlan
author_facet Li, Ke
Fang, Dengyang
Xiong, Zuming
Luo, Runlan
author_sort Li, Ke
collection PubMed
description Itraconazole (ITZ) is an anti-fungal drug that has been used in clinical practice for nearly 35 years. Recently, numerous experiments have shown that ITZ possesses anti-cancer properties. The Hedgehog (Hh) pathway plays a pivotal role in fundamental processes, including embryogenesis, structure, morphology and proliferation in various species. This pathway is typically silent in adult cells, and inappropriate activity is linked to various tumor types. The most important mechanism of ITZ in the treatment of cancer is inhibition of the Hh pathway through the inhibition of smoothened receptors (SMO), glioma-associated oncogene homologs (GLI), and their downstream targets. In this review, we discuss the mechanisms of ITZ in the treatment of cancer through inhibition of the Hh pathway, which includes anti-inflammation, prevention of tumor growth, induction of cell cycle arrest, induction of apoptosis and autophagy, prevention of angiogenesis, and drug resistance. We also discuss the clinical use of ITZ in many types of cancers. We hope this review will provide more information to support future studies on ITZ in the treatment of various cancers.
format Online
Article
Text
id pubmed-6711563
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-67115632019-11-05 Inhibition of the hedgehog pathway for the treatment of cancer using Itraconazole Li, Ke Fang, Dengyang Xiong, Zuming Luo, Runlan Onco Targets Ther Review Itraconazole (ITZ) is an anti-fungal drug that has been used in clinical practice for nearly 35 years. Recently, numerous experiments have shown that ITZ possesses anti-cancer properties. The Hedgehog (Hh) pathway plays a pivotal role in fundamental processes, including embryogenesis, structure, morphology and proliferation in various species. This pathway is typically silent in adult cells, and inappropriate activity is linked to various tumor types. The most important mechanism of ITZ in the treatment of cancer is inhibition of the Hh pathway through the inhibition of smoothened receptors (SMO), glioma-associated oncogene homologs (GLI), and their downstream targets. In this review, we discuss the mechanisms of ITZ in the treatment of cancer through inhibition of the Hh pathway, which includes anti-inflammation, prevention of tumor growth, induction of cell cycle arrest, induction of apoptosis and autophagy, prevention of angiogenesis, and drug resistance. We also discuss the clinical use of ITZ in many types of cancers. We hope this review will provide more information to support future studies on ITZ in the treatment of various cancers. Dove 2019-08-23 /pmc/articles/PMC6711563/ /pubmed/31692536 http://dx.doi.org/10.2147/OTT.S223119 Text en © 2019 Li et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Review
Li, Ke
Fang, Dengyang
Xiong, Zuming
Luo, Runlan
Inhibition of the hedgehog pathway for the treatment of cancer using Itraconazole
title Inhibition of the hedgehog pathway for the treatment of cancer using Itraconazole
title_full Inhibition of the hedgehog pathway for the treatment of cancer using Itraconazole
title_fullStr Inhibition of the hedgehog pathway for the treatment of cancer using Itraconazole
title_full_unstemmed Inhibition of the hedgehog pathway for the treatment of cancer using Itraconazole
title_short Inhibition of the hedgehog pathway for the treatment of cancer using Itraconazole
title_sort inhibition of the hedgehog pathway for the treatment of cancer using itraconazole
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6711563/
https://www.ncbi.nlm.nih.gov/pubmed/31692536
http://dx.doi.org/10.2147/OTT.S223119
work_keys_str_mv AT like inhibitionofthehedgehogpathwayforthetreatmentofcancerusingitraconazole
AT fangdengyang inhibitionofthehedgehogpathwayforthetreatmentofcancerusingitraconazole
AT xiongzuming inhibitionofthehedgehogpathwayforthetreatmentofcancerusingitraconazole
AT luorunlan inhibitionofthehedgehogpathwayforthetreatmentofcancerusingitraconazole